Cat. No：GM-C25497
Product：H_HVEM Reporter Jurkat Cell Line
Cat. No：GM-C25497
Product：H_HVEM Reporter Jurkat Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin+0.75 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+1% FBS +1% P.S
HVEM (TNFRSF14) is a member of the tumor necrosis factor (TNF) receptor family, a transmembrane protein characterized by multiple cysteine-rich domains (CRD) in its structure. HVEM is widely expressed on various immune cells, including dendritic cells, naïve T cells, B cells, NK cells, monocytes, and neutrophils.
HVEM has multiple ligands such as BTLA, CD160, LIGHT, and lymphotoxin-α (LTα). By interacting with these ligands, HVEM activates pro-inflammatory signaling pathways.
The H_HVEM Reporter Jurkat Cell Line from Genomeditech is a luciferase reporter cell line constructed based on the mechanism of action. When BTLA binds to HVEM, it activates downstream signaling pathways, leading to the expression of luciferase, a process that can be blocked by antibodies with a blocking effect. Luciferase readings indicate the activation effect of the signaling pathway and can be used to evaluate the in vitro effects of HVEM agonists, BTLA, HVEM antagonists, and other drugs.
Cat. No：GM-C25497
Product：H_HVEM Reporter Jurkat Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin+0.75 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+1% FBS +1% P.S
HVEM (TNFRSF14) is a member of the tumor necrosis factor (TNF) receptor family, a transmembrane protein characterized by multiple cysteine-rich domains (CRD) in its structure. HVEM is widely expressed on various immune cells, including dendritic cells, naïve T cells, B cells, NK cells, monocytes, and neutrophils.
HVEM has multiple ligands such as BTLA, CD160, LIGHT, and lymphotoxin-α (LTα). By interacting with these ligands, HVEM activates pro-inflammatory signaling pathways.
The H_HVEM Reporter Jurkat Cell Line from Genomeditech is a luciferase reporter cell line constructed based on the mechanism of action. When BTLA binds to HVEM, it activates downstream signaling pathways, leading to the expression of luciferase, a process that can be blocked by antibodies with a blocking effect. Luciferase readings indicate the activation effect of the signaling pathway and can be used to evaluate the in vitro effects of HVEM agonists, BTLA, HVEM antagonists, and other drugs.
